This article discusses the potential risks associated with discontinuing GLP-1 medications like Ozempic and Zepbound, as outlined by Dr. Frank Dumont. Patients may experience renewed cravings, weight regain, and worsening health markers after stopping these treatments. The artic…
Recent research emphasizes the critical role of muscle health in promoting longevity and metabolic function. Experts advocate for a comprehensive understanding of muscle quality,…
Emerging research highlights the potential of microdosing GLP-1 receptor agonists, such as semaglutide, during perimenopause to manage metabolic health. This approach may help add…
A recent study indicates that tirzepatide, a treatment for obesity, may enhance metabolism by activating brown adipose tissue in obese mice. This finding could lead to new insight…
Research into GLP-1 medications, such as Ozempic and Wegovy, indicates they may play a role in reducing cancer risk by improving metabolic health, but the evidence remains mixed a…
Recent lawsuits have emerged against the makers of GLP-1 drugs like Ozempic and Wegovy, alleging insufficient warnings about a rare vision loss condition known as NAION. While stu…
Numerous lawsuits have been initiated in the United States against companies producing GLP-1 medications, such as Ozempic and Mounjaro, claiming these drugs may lead to a rare eye…
As GLP-1 medications gain popularity for weight loss, their use among college women during sorority recruitment raises concerns about body image pressures. A recent analysis indic…
As millions of individuals take GLP-1 medications like Ozempic and Wegovy, understanding how to safely fast for Yom Kippur becomes essential. While most can participate in fasting…
A recent study from NYU Langone Health indicates that men genetically predisposed to androgenetic alopecia may face a 7% increased risk of hair loss when using GLP-1 drugs such as…
A recent review in JAMA Otolaryngology highlights the potential benefits of GLP-1 weight-loss drugs, such as tirzepatide, in reducing the severity of obesity-related sleep apnea.…
Recent research presented at the Endocrine Society’s ENDO 2026 meeting reveals that individuals taking GLP-1 weight loss medications, such as Ozempic and Wegovy, not only lost wei…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…